New Delhi: Gut-friendly bacteria, available as dietary supplements and added to various foods such as dairy products, have proven effective as a “preventive” treatment to manage both. lung and extrapulmonary acute respiratory distress syndrome (Acute respiratory distress syndrome) AIIMS's preclinical research on mice yielded research results on various lung diseases such as COVID-19, infectious diseases, and sepsis.
According to a study published in the international academic journal Clinical Immunology in January this year, preventive administration of Lactobacillus rhamnosus (LR), a lactic acid bacterium, increased the survival rate of ARDS/septic animals by up to 50% and reduced body fluids. It accumulates in the lungs. Doctors plan to conduct clinical trials on this study.
ARDS is a progressive form of respiratory failure and a life-threatening outbreak in COVID-19, pneumonia, sepsis, and trauma. It accounts for nearly 10% of intensive care unit admissions and 40% of mortality.
Despite extensive research in medicine, there is no specific treatment for ARDS. Instead, clinicians follow an evidence-based symptom management approach that includes treatment of infection, ventilation to support lung function, and general nutritional supplementation.
However, recent research has shown that dysbiosis (an imbalance in the gut microbiome that occurs when harmful bacteria outweigh good bacteria) promotes ARDS and other respiratory complications.
Rupesh Srivastava, Ph.D., associate professor of biomedical engineering, and his research group. probiotics LR as a preventive strategy to alleviate ARDS symptoms in animal models. He said this study has tremendous clinical implications in reducing the likelihood of developing ARDS-related complications and minimizing/preventing ICU admissions and associated mortality.
He detailed that an in-house rat model was developed to study the role of LR in both pulmonary and extrapulmonary ARDS (severe manifestations of sepsis). LR works its magic beyond the digestive system by producing several small molecules called short-chain fatty acids, such as butyrate. It enters the circulation, reaches the lungs and acts on various receptors responsible for regulating immune responses. This minimizes tissue damage and minimizes events such as cytokine storms in the lungs.
Doctors say that in ARDS and sepsis, white blood cells (WBCs), especially neutrophils, are a double-edged sword that causes inflammation. These white blood cells are essential in fighting infection and help heal areas of tissue damage, but delayed removal of white blood cells from the lungs causes loss of function in the air sacs, leading to fluid accumulation and the fatal condition of ARDS. It rises inside the lungs and interferes with oxygen exchange.
Dr. Srivastava said neutrophils use traps as an antibacterial toolkit and that treatment with the probiotic LR significantly reduced the formation of these infamous traps in acute respiratory distress syndrome mice.
According to a study published in the international academic journal Clinical Immunology in January this year, preventive administration of Lactobacillus rhamnosus (LR), a lactic acid bacterium, increased the survival rate of ARDS/septic animals by up to 50% and reduced body fluids. It accumulates in the lungs. Doctors plan to conduct clinical trials on this study.
ARDS is a progressive form of respiratory failure and a life-threatening outbreak in COVID-19, pneumonia, sepsis, and trauma. It accounts for nearly 10% of intensive care unit admissions and 40% of mortality.
Despite extensive research in medicine, there is no specific treatment for ARDS. Instead, clinicians follow an evidence-based symptom management approach that includes treatment of infection, ventilation to support lung function, and general nutritional supplementation.
However, recent research has shown that dysbiosis (an imbalance in the gut microbiome that occurs when harmful bacteria outweigh good bacteria) promotes ARDS and other respiratory complications.
Rupesh Srivastava, Ph.D., associate professor of biomedical engineering, and his research group. probiotics LR as a preventive strategy to alleviate ARDS symptoms in animal models. He said this study has tremendous clinical implications in reducing the likelihood of developing ARDS-related complications and minimizing/preventing ICU admissions and associated mortality.
He detailed that an in-house rat model was developed to study the role of LR in both pulmonary and extrapulmonary ARDS (severe manifestations of sepsis). LR works its magic beyond the digestive system by producing several small molecules called short-chain fatty acids, such as butyrate. It enters the circulation, reaches the lungs and acts on various receptors responsible for regulating immune responses. This minimizes tissue damage and minimizes events such as cytokine storms in the lungs.
Doctors say that in ARDS and sepsis, white blood cells (WBCs), especially neutrophils, are a double-edged sword that causes inflammation. These white blood cells are essential in fighting infection and help heal areas of tissue damage, but delayed removal of white blood cells from the lungs causes loss of function in the air sacs, leading to fluid accumulation and the fatal condition of ARDS. It rises inside the lungs and interferes with oxygen exchange.
Dr. Srivastava said neutrophils use traps as an antibacterial toolkit and that treatment with the probiotic LR significantly reduced the formation of these infamous traps in acute respiratory distress syndrome mice.